RE: Timeline7 Sep 2020 09:31
The cash injection will be used to bring through new promising targets, including BioAMP-B, for the treatment of fungal infections such as the lung condition aspergillosis.
Lead drug Lupuzor is licensed to Avion Pharmaceuticals in the US, which is funding the final-stage clinical assessment of the lupus treatment.
ImmuPharma chairman Tim McCarthy said the company was now in an “extremely robust position”.
“With value-enhancing news-flow over the next period, we are confident of creating long term shareholder value for all of our shareholders,"